

## DAY 1 - SATURDAY, JULY 8

7h30 - 8h30	Walk in, registration, coffee	NP
8h30 - 9h30	<a href="#">Welcome, introduction to the community of practice, and overview of existing evidence and tools</a>	NP
	<ul style="list-style-type: none"> <li>A brief history of the Immunization Economics community of practice: Logan Brenzel (Bill &amp; Melinda Gates Foundation)</li> <li>An overview of the Immunization Economics community of practice: Laura Boonstoppel (ThinkWell)</li> <li>Overview of the evidence base on the cost of delivering immunization: <ul style="list-style-type: none"> <li>Systematic review of new vaccine introduction cost projections: Ann Levin (Levin &amp; Morgan LLC)</li> <li>Overview of new and existing costing tools: Winthrop Morgan (Levin &amp; Morgan LLC)</li> </ul> </li> </ul>	
9h30 - 10h40	<a href="#">Evidence from bottom-up costing studies vs modelled estimates: what have we learned from C19 vaccine delivery costing?</a>	NP
	<ul style="list-style-type: none"> <li>Lessons from the COVAX global delivery cost model: Ibironke Oyatoye (UNICEF)</li> <li>The cost of delivering C19 vaccines in 6 countries: Flavia Moi (ThinkWell)</li> <li>The cost to deliver C19 vaccines in Malawi: Anika Ruisch (MSH/USAID MTaPS)</li> <li>Learnings from CVIC: Karene Yeung (WHO)</li> </ul>	
10h40 - 11h00	Coffee break	C
11h00 - 12h00	<a href="#">Immunization financing: traditional vaccines &amp; budget execution</a>	NP
	<ul style="list-style-type: none"> <li>Sustainable financing for traditional vaccines: Brendan Kwesiga (UNICEF)</li> <li>Immunization budget execution in Ghana: Emmanuel Ayifah (SEND GHANA)</li> <li>M-RITE activities to increase expenditures for operational costs in DRC and Nigeria (Grace Chee, JSI)</li> </ul>	
12h00 - 13h00	Lunch break	OP
13h00 - 14h00	<a href="#">Topic A: Driving development and introduction based on full value of vaccine assessments</a> NP	<a href="#">Topic B: Priority setting of available vaccines and vaccine innovations</a> D
	Concept, relevance, and examples of a FVVA: Philipp Lambach (WHO), JP Sevilla (HSPH), Allison Portnoy (HSPH)	CAPACITI approach, decision-support and innovation framework: Raymond Hutubessy (WHO)
14h00 - 15h30	Poster session incl coffee break	F C
15h30 - 16h30	<a href="#">Plenary discussion: collaborating as a community of practice</a>	NP
	How can we ensure alignment among our research efforts? Should we be setting a common research agenda in immunization economics? How can we improve local capacity strengthening as part of our work? Logan Brenzel (Bill & Melinda Gates Foundation), Sarah Pallas (CDC), Ulla Griffiths (UNICEF), Todi Mengistu (Gavi), Raymond Hutubessy (WHO)	
16h30 - 16h45	Announcement of the winning poster & closing: Rachel Archer (ThinkWell)	NP

NP = Nerina & Protea joint room, 1st floor
F = Freesia room, 2nd floor
D = Daisy room, 2nd floor
C = coffee area next to the Protea room, 1st floor
OP = Old Pier Café at CTICC1, accessible via the sky bridge

## DAY 2 - SUNDAY, JULY 9

7h30 - 8h30	Walk in, coffee (from 8h00), registration for new arrivals	NP
8h30 - 8h45	Summary of day 1, overview of day 2: Laura Boonstoppel (ThinkWell)	NP
8h45 - 10h00	<a href="#">Immunization financing: donor transitions, sustainability &amp; integration</a>	NP
	<ul style="list-style-type: none"> <li>Global Survey on C19 vaccination and programmatic and financial integration: Damian Walker (MSH)</li> <li>Supporting decision making on programmatic and financial sustainability at different stages of Gavi transition in Laos, Nigeria and Kenya: Sebastian Ilomuanya, Praveena Gunaratnam, Faith Mutuku, Victoria Wanjohi, Kikelomo Lambo, Sima Unogu (CHAI)</li> </ul>	
10h00 - 10h15	Group photo followed by coffee break	C
10h15 - 11h15	<a href="#">Next questions in costing and modelling methods</a>	NP
	<ul style="list-style-type: none"> <li>Costing immunization systems improvements: Sarah Pallas &amp; Roopa Darwar, (CDC)</li> <li>Cost of illness &amp; economic burden of vaccine-preventable diseases: sharing of experiences and panel discussion: Sachiko Ozawa (University of North Carolina at Chapel Hill), Rachel Hounsell (University of Oxford), Sarah Pallas (CDC)</li> </ul>	
11h15 - 12h15	<a href="#">Topic A: Methods and practical challenges in costing HPV and malaria vaccine programs</a> NP	<a href="#">Topic B: Health Technology Assessment of COVID-19 vaccination in Nigeria</a> D
	Learning from 6 HPV costing studies and RTS,S vaccine costing: Mercy Mvundura, Rose Slavkovsky, Ranju Baral (PATH)	Benjamin Uzochukwu, Chinyere Okeke (University of Nigeria, Nsukka), Sergio Torres Rueda (London School of Hygiene and Tropical Medicine)
12h15 - 13h15	Lunch break	OP
13h15 - 14h45	<a href="#">Cost &amp; sustainability of reaching zero-dose children</a>	NP
	<ul style="list-style-type: none"> <li>Financial sustainability of reaching zero-dose children, scoping review and framework: Sarah Tougher (UNICEF)</li> <li>How much does it cost to reach zero-dose and under-immunized children? A case study of the Electronic Community Health Information System in Uganda: Carol Kanya (IDRC Kampala)</li> <li>The costs of using drones to transport vaccines to hard-to-reach areas in DRC: Louis Tshituka (VillageReach)</li> <li>Panel discussion: what are the best methods for estimating the cost and impact of strategies to reaching zero-dose children? Ijeoma Edoke (University of the Witwatersrand, Johannesburg), Stephen Resch (HSPH), Ulla Griffiths (UNICEF)</li> </ul>	
14h45 - 15h10	Coffee break	C
15h10 - 16h30	<a href="#">Fostering use of evidence</a>	NP
	<ul style="list-style-type: none"> <li>Use of modelling evidence for policy and programming: Kaja Abbas (VIMC)</li> <li>Using IA2030 impact and cost estimates for future decisions: Yoonie Sim (WHO)</li> <li>Using health and economic impact evidence at Gavi to inform investment decisions and resource mobilization: Todi Mengistu (Gavi)</li> <li>Learnings from the G20 Joint Finance &amp; Health Task Force for pandemic preparedness (Raymond Hutubessy, WHO)</li> </ul>	
16h30 - 17h00	Summary & closing: Rachel Archer & Laura Boonstoppel (ThinkWell)	NP



F Posters are on display in the Freesia room. To vote, use the QR code or go to <https://www.propofcs.com/survey/t/?title=t6txl>

#	Poster title	Presenter
<b>Theme A: Cost effectiveness, cost of illness, and other economic evaluations</b>		
1	<a href="#">Understanding the cost effectiveness of COVID-19 vaccination in Nigeria</a>	Chinyere Okeke, <i>University of Nigeria</i>
2	<a href="#">Comprehensive estimates of cost-effectiveness support rotavirus vaccine introduction &amp; expansion</a>	Marcia Weaver, <i>University of Washington</i>
3	<a href="#">Comparative cost-effectiveness analysis of community engagement interventions in LMICs</a>	Monica Jain, <i>International Initiative for Impact Evaluation</i>
4	<a href="#">Economic impact of Rotavirus vaccination: a comparative modelling study</a>	Phetsavanh Chanthavilay, <i>National University of Singapore</i>
5	<a href="#">Economic burden associated with adverse effects due to COVID-19 vaccination data from the Queensland COVID-19 vaccination program statewide study</a>	Qing Xia, <i>Queensland University of Technology</i>
6	<a href="#">Economic and health impact of Pneumococcal vaccination in controlling the growth of antimicrobial resistance in Ethiopia, China, and Indonesia</a>	Sachiko Ozawa, <i>University of North Carolina, UNC Gillings School of Global Public Health</i>
7	<a href="#">Cost-effectiveness of introducing HPV 9-valent vaccine for women in Japan.</a>	Shunya Ikeda, <i>International University of Health and Welfare</i>
8	<a href="#">Global cost-effectiveness of potential maternal immunisation against Group B Streptococcus.</a>	Simon Proctor, <i>London School of Hygiene &amp; Tropical Medicine</i>
9	<a href="#">Incremental cost and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in India</a>	Susmita Chatterjee, <i>George Institute for Global Health</i>
<b>Theme B: Costing</b>		
10	<a href="#">Systematic review of new vaccine introduction cost projections</a>	Ann Levin, <i>Levin and Morgan LLC</i>
11	<a href="#">The cost of delivering COVID-19 vaccines in The Philippines</a>	Christina Banks, <i>ThinkWell</i>
12	<a href="#">The cost of delivering COVID-19 vaccines in Cote D'Ivoire</a>	Elise Smith, <i>Genesis Analytics</i>
13	<a href="#">The cost of delivering COVID-19 vaccines in The Democratic Republic of the Congo</a>	Flavia Moi, <i>ThinkWell</i>
14	<a href="#">Implementation of evidenced-based midwifery practices under the midwife-led quality improvement framework in Nairobi, Kenya - analysis of costs and intermediate outcomes</a>	John Kiragu, <i>Kenyatta National Hospital &amp; University of Nairobi</i>
15	<a href="#">WHO economic tools on HPV vaccine strengthen country and regional capacity to generate economic evidence for immunization programmes</a>	Karene Hoi Ting Yeung, <i>WHO</i>
16	<a href="#">The cost of delivering COVID-19 vaccines in Vietnam</a>	Van M Nguyen, <i>Hanoi University of Public Health</i>
<b>Theme C: Equity and vaccine delivery</b>		
17	<a href="#">A review of the cost of identifying and reaching zero-dose children in vulnerable communities against existing health facility budgets</a>	Fredrick Luwaga, <i>CHAI</i>
18	<a href="#">Equity impact of HPV vaccination</a>	Kaja Abbas, <i>London School of Hygiene &amp; Tropical Medicine</i>
19	<a href="#">Revolutionising vaccine transport: introduction of a novel technology to protect the cold chain in Tanzania</a>	Mariam Johari, <i>Nexleaf Analytics</i>
<b>Theme D: Immunization financing &amp; public financial management</b>		
20	<a href="#">Costing, planning, budgeting, and resource mobilization for immunization program in Indonesia's decentralized setting</a>	Lili Nur Indah Sari, <i>CHAI</i>
21	<a href="#">A literature review of subnational health financing constraints and opportunities for improving integrated service delivery – Uganda case study</a>	Lorraine Kabunga, <i>CHAI</i>
22	<a href="#">Describing the influence of public financial management rules and procedures on vaccine financing of the Government of Sierra Leone</a>	Noemi Schramm, <i>Centre Africain d'Etudes Supérieures en Gestion</i>
23	<a href="#">Indonesia immunization financing landscape</a>	Putri Herliana, <i>CHAI</i>
<b>Theme E. Use of evidence for decision-making</b>		
24	<a href="#">Optimal investment for outcome-oriented immunization program</a>	Apurva Pawar, <i>UNICEF</i>
25	<a href="#">Guidelines for the economic evaluation of vaccination programs in Canada</a>	Beate Sander, <i>University Health Network and University of Toronto</i>
26	<a href="#">Uganda immunization investment case</a>	Charlotte Muheki, <i>ThinkWell</i>
27	<a href="#">How do we measure the return-on-investment (ROI) of Typhoid Conjugated Vaccine and Oral Cholera Vaccine ?</a>	Salin Sriudomporn, <i>International Vaccine Access Center</i>